GC180 Benign Prostatic Hyperplasia, Bladder Outlet Obstruction And Urinary Retention
Benign prostatic hyperplasia is a non-malignant enlargement of the prostate gland that can cause bladder outlet obstruction and, if untreated, may progress to acute or chronic urinary retention.
Benign Prostatic Hyperplasia, Bladder Outlet Obstruction & Urinary Retention
This GC 180 lecture is a high-yield urology lecture that covers three deeply interconnected topics that form one of the most common surgical presentation pathways you'll encounter: a man who cannot pass water. The lecture is structured as:
- Physiology of micturition – how normal voiding works (storage vs. emptying)
- Pathophysiology of urinary retention – what goes wrong and why
- Clinical management of urinary retention – the practical approach from A&E to definitive care
The unifying concept: the lower urinary tract has two jobs — store urine and expel urine. When either function fails (usually due to obstruction or impaired detrusor contractility), the patient retains urine. BPH is the most common cause of bladder outlet obstruction (BOO) in men, and BOO is the most common cause of acute urinary retention (AROU). This lecture connects to GC 209 (urinary incontinence/OAB), GC 183 (urological malignancies including CA prostate), and the paediatric urology lecture (GC 213).
Learning objectives from the lecture [1]:
- Learn the pathophysiology of micturition – structure and function, storage vs emptying phase
- Understand how urinary retention develops
- Grasp the concept of BOO
- Discuss the clinical management of urinary retention
1. Anatomy of the Lower Urinary Tract
The lower urinary tract differs between sexes [1]:
- Male: Urinary Bladder + Prostate + Urethra
- Female: Urinary Bladder + Urethra
This anatomical difference is crucial — the prostate sits between the bladder neck and the external sphincter in males, wrapping around the prostatic urethra. This is precisely why BPH causes obstruction in men but not women. In women, the shorter urethra and absence of prostate mean BOO is much less common, and retention is more often due to detrusor underactivity.
| Zone | Location | Clinical Significance |
|---|---|---|
| Transitional zone | Surrounds prostatic urethra | BPH arises here — grows inward → compresses urethra early → symptomatic |
| Peripheral zone | Posterior, largest zone | Prostate cancer arises here — grows outward → presents late |
| Central zone | Surrounds ejaculatory ducts | Less clinically relevant |
| Anterior fibromuscular stroma | Anterior | Non-glandular |
BPH is not considered a premalignant lesion. BPH and prostate cancer can coexist, however, and the zone distinction is not absolute: BPH classically begins in the transition zone, whereas most cancers arise in the peripheral zone. Do not use a benign-feeling enlarged prostate to exclude cancer.
The slide cross-section separates the continence mechanism into more than a single “sphincter”:
- The detrusor forms the bladder wall; the trigone is the smooth triangular base between the ureteric orifices and bladder neck.
- The proximal outlet is the bladder neck/proximal urethral smooth-muscle mechanism, strongly influenced by sympathetic α1 tone.
- The distal outlet includes urethral smooth muscle plus the intrinsic rhabdosphincter and peri-urethral striated muscle under somatic (pudendal) control.
This layered anatomy explains why continence can persist when one component is weak, and why coordinated relaxation of both smooth and striated outlet components is required for efficient voiding.
2. Physiology of Micturition
Normal voiding has two phases [1]:
| Phase | Requirements |
|---|---|
| STORAGE | Accommodation of urine at low pressure with appropriate sensation |
| Bladder outlet remains closed at rest and during increased intra-abdominal pressure | |
| No involuntary bladder contraction | |
| EMPTYING | Coordinated contraction of bladder smooth muscle of adequate magnitude and duration |
| Lowering of resistance at the level of smooth and striated sphincter | |
| Absence of anatomic obstruction |
Why this matters: Each requirement for normal voiding can fail. When storage fails → incontinence. When emptying fails → retention. This is the framework for understanding ALL lower urinary tract pathology.
Reading the pressure–volume diagrams
The normal bladder changes from a folded, relatively flat reservoir to a rounded chamber while pressure rises only slightly. That near-horizontal pressure–volume relationship represents high compliance (compliance = ΔV/ΔP): a large increase in volume for little increase in detrusor pressure. Poor compliance is dangerous because filling pressure rises and may be transmitted to the upper urinary tract.
The lecture also uses a thin-wall approximation of Laplace's law:
wall tension T ≈ Pves × radius / (2 × wall thickness)
For the same pressure, a larger bladder radius requires more wall tension; a thicker detrusor wall reduces the tension per unit thickness. This is a conceptual model, not a bedside calculation.
2.2 Innervation of the Lower Urinary Tract
Three nerve systems control the LUT [1]:
| System | Origin | Target | Receptor | Effect |
|---|---|---|---|---|
| Sympathetic | T10-L2 (hypogastric nerve) | Detrusor | β3-adrenergic | Relaxation (storage) |
| Bladder neck / Prostate | α1-adrenergic | Contraction (continence) | ||
| Parasympathetic | S2-S4 (pelvic nerve) | Detrusor | M3 muscarinic | Contraction (voiding) |
| Somatic | Onuf's nucleus → S2-4 (pudendal nerve) | External sphincter (rhabdosphincter) | Nicotinic | Contraction (continence) |
High-Yield Receptor Table
This receptor table is the pharmacological basis for ALL BPH/LUTS medications:
- α1 blockers (tamsulosin) → relax bladder neck/prostate → relieve dynamic obstruction
- β3 agonists (mirabegron) → relax detrusor → improve storage (used in OAB)
- Antimuscarinics (oxybutynin) → block M3 → reduce involuntary detrusor contractions (OAB), but can CAUSE retention
- 5α-reductase inhibitors (finasteride) → reduce DHT → shrink prostate → relieve static obstruction
Afferent fibres [1]:
- Present in hypogastric, pelvic (majority), and pudendal nerves
- Myelinated Aδ fibres (sense normal bladder distension)
- Unmyelinated C-fibres (sense irritation/pain; normally silent, become active in pathology)
C-fibre activation involves release of ATP, tachykinins, and PGE₂, acting on P2X₂/₃, neurokinin, and prostanoid receptors respectively [1].
- All relay to higher centres
Two key centres [1]:
- Pontine Micturition Centre (PMC / Barrington's nucleus) – the "on-off switch" for voiding
- Suprapontine control (Cerebral cortex) – voluntary inhibition/initiation
During storage [1]:
- Myelinated Aδ sensory fibres send low-level afferent signals (vesicosympathetic 'storage' reflex)
- Sympathetic pathway: ACTIVE (+ve)
- Parasympathetic pathway: INHIBITED (-ve)
- Somatic pathway: ACTIVE (+ve)
- Results in:
- Detrusor relaxation (β3-adrenergic)
- Internal urethral sphincter contraction (α1-adrenergic)
- External urethral sphincter contraction (nicotinic)
Additionally, sympathetic firing during storage modulates transmission in bladder ganglia (ganglionic inhibition), further suppressing parasympathetic drive to the detrusor [1].
Why this works: Low-level bladder filling activates sympathetic tone via a spinal reflex. The bladder relaxes to accommodate urine (receptive relaxation following Laplace's Law: T = P×R / 2d), while both sphincters contract to maintain continence. The parasympathetic drive to the detrusor is actively suppressed.
During voiding [1]:
- Higher level of afferent firing signals to PMC + "OK" signal from cerebral cortex
- Ascending afferent input from the spinal cord passes through the periaqueductal gray (PAG) before reaching the PMC [1]
- The on-off switch is 'flipped' — PMC sends signals to:
- Sympathetic: INHIBITED (-ve)
- Parasympathetic: ACTIVE (+ve)
- Somatic: INHIBITED (-ve)
- Results in:
- Detrusor contraction (M3 muscarinic)
- Internal urethral sphincter relaxation
- External urethral sphincter relaxation
Voiding reflex pathway [1]: Critical level of afferent activity from tension receptors in bladder → PMC (+ cortical input) → three simultaneous outputs:
- Activation of sacral parasympathetic efferent to bladder → Contraction of detrusor
- Activation of sacral parasympathetic to urethra → Relaxation of urethral smooth muscle
- Inhibition of somatic pathway to sphincter → Relaxation of striated sphincter → Voiding
In spinal cord injury (SCI), the descending control from PMC is interrupted [1]:
- The detrusor contracts BUT the sphincter contracts simultaneously (should relax)
- This is called Detrusor Sphincter Dyssynergia
- Results in extremely high intravesical pressures → upper tract damage
Why DSD occurs: The PMC normally coordinates detrusor contraction WITH sphincter relaxation as a single package. When the spinal cord is damaged above the sacral segments (suprasacral lesion), local sacral reflexes can still trigger detrusor contractions, but the inhibitory signal to the sphincter (which comes from the PMC) cannot get through. Both muscles fire at once.
SCI and Bladder
Don't confuse the phases:
- Spinal shock phase (acute SCI) → areflexic bladder → AROU/overflow incontinence (everything shuts down)
- After spinal shock resolves → hyperreflexic bladder with DSD → urge incontinence ± high-pressure retention → risk of reflux nephropathy
- Sacral cord/cauda equina lesion → areflexic bladder (permanent) → overflow incontinence
3. Pathophysiology of Urinary Retention
Two types of retention [1]:
| Feature | Acute Retention (AROU) | Chronic Retention (CROU) |
|---|---|---|
| Onset | Sudden | Gradual |
| Pain | Painful | Usually painless |
| Symptoms | Cannot pass urine at all | Vague lower abdominal distension |
| Example | Benign prostatic obstruction | Hypocontractile bladder |
| Bladder | Tense, tender | Large, non-tender |
| Overflow incontinence | Possible | Common |
AROU is defined as "sudden inability to pass urine" — a common reason for hospital admission in Urology. Can occur in both males and females [1].
Historical lecture data
The incidence figures and aetiology percentages below come from older cohorts reproduced in the slides (principally 1980s–1990s studies). They are useful for the lecture's qualitative message — risk rises steeply with age and BPH is a leading cause in men — but should not be treated as current Hong Kong population estimates or fixed diagnostic priors.
Incidence in men [1]:
- ~7 per 1,000 men per year
- Cumulative 4-year probability: 3%
- Over 5 years: 10% of men in their 70s and ~30% of men in their 80s will experience AROU
Risk factors for male AUR (Olmsted County Study) [1]:
- Increasing age
- Increasing prostate size
- Increasing BPH symptoms
- Decreasing maximal urine flow rate
Incidence in women [1]:
- ~3 per 100,000 per year (much rarer than in men)
- Bladder outlet obstruction less common
- A proportion has detrusor underactivity (DUA)
Three mechanisms of AROU [1]:
| Mechanism | Description | Examples |
|---|---|---|
| Increased resistance to urine flow | ||
| — Mechanical | Physical blockage | Urethral stricture, clots, stone |
| — Dynamic | Functional narrowing | Enlarged prostate / bladder neck tone |
| — Functional | Neurological dysfunction | Neuropathic bladder |
| Impaired detrusor contractions | Cannot generate adequate voiding pressure | Drug-induced (antimuscarinics), bladder overdistension (post-anaesthesia), neuropathic bladder |
| Combination | Both obstruction + poor contractility | Most common in practice |
3.4 Causes of AROU
Common obstructive causes in males [1]:
- BPH (most common, ~53%)
- Cancer of prostate
- Bladder/Urethral stone
- Bladder neck stenosis (usually after previous prostate surgery)
- Urethral stricture (iatrogenic or infection/inflammation)
- Phimosis
- Bladder tumour
- Clot retention (severe gross haematuria)
Aetiology breakdown of male AUR [1]:
| Cause | Percentage |
|---|---|
| BPH | 53% |
| Constipation | 7.5% |
| Carcinoma of prostate | 7% |
| Urethral stricture | 3.5% |
| Clot retention | 3% |
| Neurological disorders | 2% |
| Post-operative | 2% |
| Calculus | 2% |
| Drugs | 2% |
| Infection | 2% |
| Miscellaneous/unknown | 16% |
Common causes in females [1]:
- Detrusor hypocontractility — exclude DM
- Neurogenic bladder
- Idiopathic
Neurogenic bladder: bladder dysfunction associated with other neurological deficit, e.g. SCI, CVA, Parkinsonism [1]
Comprehensive causes of female AUR [1]:
| Category | Causes |
|---|---|
| Anatomical | Organ prolapse (e.g. cystocele); mass effect (gynaecological tumour, urological tumour, constipation); bladder neck stenosis |
| Drugs | Opiates, antimuscarinics, antipsychotics, α-adrenergic agonists |
| Operative | Pain, anaesthetic-related (e.g. epidural anaesthesia), incontinence surgery |
| Neurological | Cord trauma, degenerative neurological disease (e.g. multiple sclerosis), cauda equina syndrome, Fowler's syndrome |
| Infective | UTI, genital herpes |
Precipitating factors of AROU [1]:
- Constipation
- UTI
- Anaesthesia / analgesia
- Immobility
- Painful peri-anal conditions (e.g. thrombosed haemorrhoids, perianal abscess)
- Excessive fluid intake (esp. alcohol)
- Drugs:
- With anticholinergic S/E: antipsychotic, antispasmodics, H1 antihistamines, antidepressants, ipratropium, disopyramide
- With sympathomimetic S/E: cold medications, MDMA
Drug-Induced AROU
This is a classic exam trap. ANY drug with anticholinergic properties can precipitate AROU in a man with pre-existing BPH. Common culprits: first-generation antihistamines (chlorpheniramine), tricyclic antidepressants, opioids. Sympathomimetics (e.g. pseudoephedrine in cold medications) increase α1-mediated bladder neck tone → dynamic obstruction.
Important distinction [1]: Urinary retention ≠ anuria or oliguria Causes of no urine production:
- Pre-renal ARF: dehydration, shock
- Renal ARF: drug-induced, ATN, nephritis
In retention, the kidneys ARE making urine — it just can't get out. The bladder is full and distended. In anuria/oliguria, the bladder is empty because the kidneys aren't producing urine.
4. Bladder Outlet Obstruction (BOO)
BOO is more common in men [1]:
| Sex | Causes |
|---|---|
| Male — Anatomical | BPH, urethral stricture, stone, tumour |
| Male — Functional | Sphincter dyssynergia |
| Female | Post-operation (e.g. after surgery for stress incontinence) |
Key Conceptual Distinction (Hald Diagram)
Three commonly confused concepts [2]:
- BOO = urodynamic diagnosis (high detrusor pressure + low flow rate)
- LUTS = clinical symptoms (can be from BOO, OAB, or other causes)
- BPE (benign prostatic enlargement) = an anatomical increase in prostate volume, estimated on examination or measured by imaging
The three circles overlap only partly. BPH is the histological process; BPE is enlargement; BPO is obstruction attributed to the prostate; and BOO is the broader functional/urodynamic endpoint. Not all LUTS is prostatic, not all enlarged prostates obstruct, and obstruction may be minimally symptomatic. Treatment must target the patient's actual symptom mechanism and risk.
Complications progress from bladder → upper tract [1]:
- Retention of urine — acute or chronic
- Recurrent UTI
- Formation of bladder calculi
- Hydroureter and hydronephrosis
- Renal impairment / ARF (Obstructive uropathy)
Why this progression occurs: Chronic obstruction → increased residual urine → stasis → UTI and stone formation. Chronically elevated intravesical pressure → transmitted backwards to ureters and kidneys → hydroureter/hydronephrosis → if bilateral and persistent → obstructive nephropathy → renal failure.
What the slide's bladder-wall sequence shows: chronic outlet resistance first drives detrusor hypertrophy and visible trabeculation. Mucosa may then herniate between muscle bundles to form acquired diverticula, which empty poorly and promote infection or stone formation. Upper-tract dilatation and renal impairment are features of high-pressure/advanced disease, not inevitable consequences of every case of BPE or LUTS.
4.4 Investigating BOO
Uroflowmetry [1]:
- NOT sufficient to diagnose outlet obstruction
- Cannot distinguish obstruction from poor detrusor contractility
- Qmax 15-20 mL/sec = "normal"
- Qmax < 10 mL/sec = "abnormal"
- 47% of BOO patients have Qmax < 10 mL/s (PPV 70%)
- 82% of BOO patients have Qmax < 15 mL/s (PPV 67%)
- 18% are obstructed despite Qmax > 15 mL/s
Visual trace interpretation: a normal void typically produces a smooth, single bell-shaped flow curve. Obstruction often produces a prolonged, low-amplitude plateau; an interrupted or fluctuating trace may reflect abdominal straining, sphincter activity, or intermittent flow and is not specific for BPO. Always read the flow curve together with voided volume and post-void residual (PVR), and ask whether the void was representative.
Age- and sex-specific lowest acceptable Qmax values [1]:
| Age (years) | Minimum voided volume (mL) | Male (mL/s) | Female (mL/s) |
|---|---|---|---|
| 4–7 | 100 | 10 | 10 |
| 8–13 | 100 | 12 | 15 |
| 14–45 | 200 | 21 | 18 |
| 46–65 | 200 | 12 | 15 |
| 66–80 | 200 | 9 | 10 |
These are historical nomogram values reproduced in the lecture, not universal modern cut-offs. Flow depends strongly on voided volume, age and sex.
Current interpretation: uroflowmetry is a non-invasive functional test, not a stand-alone diagnosis. The 2026 EAU male-LUTS guideline advises interpreting Qmax, curve shape, voided volume and PVR together; a voided volume over about 150 mL is preferred, and an unexpectedly low or unrepresentative trace should be repeated. A man with weak detrusor contraction and a man with BOO can both have low Qmax.
Urodynamic studies [1]:
- Study function of the lower urinary tract
- Parameters measured: intravesical pressure, rectal pressure, detrusor pressure (deduced), uroflow rate, sphincter function EMG, bladder volume, cystogram/reflux (video)
- BOO = "Low uroflow rate with high detrusor pressure" = Urodynamic diagnosis
The diagram's key derived variable is Pdet = Pves − Pabd: a bladder catheter measures total intravesical pressure (Pves), a rectal catheter estimates abdominal pressure (Pabd), and subtraction estimates detrusor-generated pressure. Flow is recorded simultaneously; EMG and fluoroscopic video can add sphincter coordination and anatomical information when indicated.
On a pressure-flow plot (Pdet at Qmax vs Qmax), results are classified into three diagnostic zones [1]:
- Obstructed — high Pdet, low Qmax (upper region)
- Equivocal — intermediate values
- Unobstructed — low Pdet, normal Qmax (lower region)
| Diagnosis | Flow Rate | Detrusor Pressure |
|---|---|---|
| BOO | ↓ Low | ↑ High |
| Detrusor underactivity | ↓ Low | ↓ Low |
| Normal | Normal | Normal |
BOO is a urodynamic diagnosis [1]
Pressure–flow testing is the reference test when the mechanism matters, but it is invasive and is not required in every man with uncomplicated LUTS. The same current EAU guideline recommends selective use when the pathophysiology is uncertain or the result would change invasive management. In men, the optional Abrams–Griffiths index is BOOI = Pdet@Qmax − 2(Qmax) (> 40 obstructed, 20–40 equivocal, < 20 unobstructed); thresholds should not be extrapolated uncritically to women.
5. Benign Prostatic Hyperplasia (BPH)
BPH is a histological diagnosis: benign proliferation of both glandular epithelium and stromal tissue in the transitional zone of the prostate [3]. It is androgen-dependent, driven primarily by dihydrotestosterone (DHT), which is converted from testosterone by 5α-reductase within the prostate.
BPH causes obstruction through two components [3]:
- Static component: Physical enlargement of the prostate compresses the urethra (mediated by DHT → stromal hyperplasia) → target of 5α-reductase inhibitors (finasteride, dutasteride)
- Dynamic component: Smooth muscle contraction in the prostate/bladder neck via α1 receptors → target of α1-blockers (tamsulosin, alfuzosin)
Organized by level [3]:
| Level | Complication |
|---|---|
| Prostate | Bleeding (ruptured dilated bladder neck veins) |
| Bladder | AROU, recurrent UTI, bladder stone, diverticulum, chronic ROU ± overflow incontinence |
| Upper tract | Hydronephrosis, obstructive uropathy, renal failure |
| Feature | BPH | CA Prostate |
|---|---|---|
| Size | Often symmetrically enlarged; DRE volume estimate is imprecise | Variable; may be normal |
| Consistency | Smooth, firm-elastic/rubbery | Hard, irregular or asymmetric |
| Median sulcus | May be preserved or flattened by enlargement | May be distorted, but this is not diagnostic |
| Nodules | No suspicious hard nodule | A hard nodule is suspicious |
| Tenderness | Non-tender | Non-tender (unless prostatitis) |
| Mobility | Mobile | May be fixed |
DRE supports risk assessment but neither a benign-feeling gland nor a preserved sulcus excludes cancer.
A validated 7-question tool quantifying LUTS severity [2]:
- 4 voiding symptoms: incomplete emptying, intermittency, weak stream, straining
- 3 storage symptoms: frequency, urgency, nocturia
- Plus 1 quality-of-life question
- Score interpretation: Mild 0-7, Moderate 8-19, Severe 20-35
- Used to guide treatment and monitor response — NOT a diagnostic tool
| Class | Examples | Mechanism | Indication | Key Side Effects |
|---|---|---|---|---|
| α1-blockers | Tamsulosin, Alfuzosin, Terazosin, Doxazosin | Relax smooth muscle at bladder neck/prostate (dynamic component) | Moderate–severe LUTS; rapid symptom benefit | Dizziness/postural hypotension; ejaculatory dysfunction (especially more α1A-selective agents); floppy-iris risk |
| 5α-reductase inhibitors | Finasteride, Dutasteride | Inhibit testosterone → DHT conversion; shrink prostate (static component) | Large prostate; takes 6-12 months to work | Erectile dysfunction, decreased libido, gynaecomastia; halves PSA |
| Antimuscarinics | Oxybutynin, Solifenacin | Reduce detrusor muscarinic activation | Predominantly storage symptoms after assessing emptying | Dry mouth, constipation, cognitive adverse effects; may increase PVR |
| PDE5 inhibitors | Tadalafil | Smooth muscle relaxation (mechanism unclear) | LUTS + concomitant erectile dysfunction | Headache, flushing |
Tamsulosin is relatively α1A-selective; alfuzosin is clinically uroselective despite not being receptor-subtype selective, whereas doxazosin and terazosin are systemic non-selective α1 blockers. For antimuscarinics, assess baseline PVR and recheck if voiding worsens; the EAU male-LUTS guideline gives a weak recommendation not to use them when PVR is > 150 mL rather than the lecture note's former 200 mL “absolute contraindication.”
- TURP (transurethral resection of prostate) — a well-established reference operation, especially for a roughly 30–80 mL gland, but no longer a universal one-size-fits-all “gold standard”
- Indications for surgery: failed medical therapy, recurrent AROU, recurrent UTI, bladder stones, renal impairment from BOO, recurrent haematuria
- Complications: TUR syndrome (hyponatraemia from irrigation fluid absorption), retrograde ejaculation, urethral stricture, bladder neck stenosis
Procedure choice now depends on gland size/anatomy, bleeding risk, priorities around ejaculation and retreatment, local equipment, and surgeon expertise. Enucleation (for example HoLEP) is size-independent in experienced hands, while several resection, vaporisation and minimally invasive options exist; discuss benefits and trade-offs rather than assuming TURP for every patient (AUA BPH guideline, 2023 amendment).
6. Clinical Management of Urinary Retention
History 1 [1]:
- Confirm urinary retention — check first catheterized urine volume
- Painful vs painless retention
- First episode or recurrent
- Preceding LUTS
- Other BPH complications: gross haematuria, UTI (fever/dysuria), bladder/urethral stone (strangury), renal impairment (uraemic symptoms)
History 2 [1]:
- Precipitating factors of AROU
- Lower limb weakness/numbness + overflow incontinence/faecal incontinence → SUSPECT ACUTE SPINAL CORD COMPRESSION
- Constitutional symptoms / multiple bone pain → Suspect metastatic CA prostate
History 3 [1]:
- Medications: BPH medications (alpha blockers / 5-ARI), anticholinergics etc.
- Previous prostate surgery (e.g. TURP) or urethral instrumentation
- History of STD especially gonococcal/non-gonococcal urethritis (→ urethral stricture)
- History of CVA / Parkinsonism / Spinal surgery (→ neurogenic bladder)
Red Flags in AROU
Always ask about lower limb weakness/numbness and faecal incontinence [1]. If present → suspect acute spinal cord/cauda equina compression → EMERGENCY MRI and neurosurgical referral.
Physical Examination 1 [1]:
- Vital signs: Is the patient septic? Is the patient uraemic?
- Abdominal exam: Palpable urinary bladder (if not yet catheterized), any phimosis
- Urethral catheter output: any gross haematuria?
Physical Examination 2 [1]:
- Digital Rectal Examination (DRE):
- Anal tone and peri-anal sensation (test sacral nerve integrity)
- Prostate estimated size
- Clinical features suspicious of prostate cancer (hard, nodular, obliterated sulcus)
- Prostate tenderness (prostatitis)
- Faecal impaction (precipitating cause)
- Any painful peri-anal conditions
- Lower limb neurological deficit
Management 1 — Immediate decompression of bladder [1]:
- Urethral catheterization (first line)
- Suprapubic catheterization (SPC) (if urethral route fails or contraindicated)
SPC Indications [1]:
- Failed urethral catheterization
- History of urethral trauma (e.g. straddle injury)
SPC Contraindications [1]:
- Non-distended bladder
- Uncorrected bleeding tendency
- Known/suspected urothelial cancer
SPC Complications [1]:
- Bowel perforation
- Rectal injury (overshoot)
- Haematuria
Safe decompression sequence
- Confirm a distended bladder clinically and/or with bedside ultrasound when the diagnosis is uncertain. There is no single PVR threshold that by itself proves BOO or dictates treatment; symptoms and context matter.
- Provide analgesia and perform a lubricated, aseptic urethral catheterisation by a trained clinician. Record the catheter type/size, drainage volume and urine appearance. Do not inflate the balloon until intravesical placement is secure.
- Once placed, allow free, complete drainage; routine intermittent clamping is unnecessary. A randomised trial found no reduction in haematuria or circulatory collapse with gradual rather than rapid drainage (Boettcher et al., 2013).
- After large-volume or chronic high-pressure retention, monitor observations, urine output, creatinine and electrolytes for haematuria, hypotension and post-obstructive diuresis. Escalate persistent high-output diuresis or electrolyte/volume disturbance.
- If a catheter does not pass easily, stop repeated blind force. Seek experienced help for an appropriate curved-tip catheter or guidewire/cystoscopic placement; use SPC when urethral drainage is impossible or contraindicated. The equipment photograph shows a trocar SPC kit, but this is a sterile invasive procedure requiring a confidently localised/distended bladder and trained placement, preferably with ultrasound guidance where anatomy is uncertain.
Trauma changes the catheter plan
Blood at the meatus, pelvic fracture, significant perineal/straddle trauma, perineal bruising or new difficulty passing a catheter should raise concern for urethral injury. Avoid repeated blind attempts and obtain urgent urological assessment with retrograde urethrography and/or cystourethroscopy. The 2026 EAU Urological Trauma guideline identifies retrograde urethrography as the standard early test in men; urinary diversion may be urethral or suprapubic under expert/image-guided conditions.
For presumed BPH-related AUR, start an α blocker if appropriate before a planned trial without catheter (TWOC); the exact catheter duration/TWOC timing follows local urology protocol. NICE CG97 recommends immediate catheterisation and an α blocker before catheter removal. Do not give routine prophylactic antibiotics merely because a short- or long-term catheter is present; culture and treat symptomatic infection according to local antimicrobial guidance (NICE NG113).
Investigations [1]:
- CBP (complete blood picture)
- L/RFT (liver and renal function tests)
- CSU × C/ST (catheter specimen of urine for culture and sensitivity)
- KUB (plain X-ray of kidneys, ureters, bladder)
- No PSA — likely falsely elevated (in the acute setting with catheter in situ, manipulation, UTI)
Current, indication-led work-up: the slide's blanket “CBP/LFT/RFT, catheter urine culture, KUB” list is historical rather than a routine panel for every patient.
- Perform urinalysis; send culture if infection is clinically suspected. Check FBC when sepsis or bleeding is plausible, and creatinine/electrolytes when retention, renal impairment or post-obstructive diuresis is a concern.
- Use renal/bladder ultrasound when there is renal impairment, a very large/chronic retention, palpable bladder after voiding, recurrent infection/stones, or concern for hydronephrosis. Plain KUB radiography and liver tests are not routine retention tests.
- Uncomplicated LUTS does not require routine upper-tract imaging or cystoscopy. NICE advises creatinine/eGFR at initial LUTS assessment only when renal impairment is suspected; retention is itself a reason for specialist assessment (NICE CG97).
PSA: defer and interpret — not 'never'
The slide's “no PSA” means do not use an acutely confounded result as a cancer screen. Acute retention can moderately raise PSA, and febrile UTI/prostatitis can raise it substantially. If PSA is clinically indicated, obtain/repeat it after the acute episode and infection have resolved, under standardised conditions without recent manipulation; the interval should follow the clinical context and local pathway rather than a universal six-week rule. The EAU prostate-cancer diagnostic guideline recommends repeating a moderately raised PSA (3–10 ng/mL with non-suspicious examination) after about four weeks and explicitly lists AUR, UTI and manipulation as confounders. Atraumatic catheterisation alone should not automatically end appropriate cancer evaluation.
| Category | Symptoms | Mnemonic | Typical Cause |
|---|---|---|---|
| Storage (Irritative) | Frequency, Urgency (± urge incontinence), Nocturia | FUN | OAB, UTI, stone, tumour, post-RT |
| Voiding | Slow/weak stream, splitting/spraying, intermittency, hesitancy, straining, terminal dribble | DISH is a memory aid, not a formal definition | BPO/BOO, urethral stricture, detrusor underactivity |
| Post-micturition | Feeling of incomplete emptying, post-micturition dribble | Residual urethral urine or impaired emptying |
Terminal dribble (a prolonged final part of the stream) is a voiding symptom; post-micturition dribble is leakage after voiding has finished. Neither symptom alone proves obstruction.
From GC 209 [4]:
Chronic retention with overflow incontinence may be complicated with UTI, bladder stone formation. Chronic retention caused by BPH and other causes of outlet obstruction may eventually lead to obstructive uropathy and deterioration of renal function.
Overflow incontinence is the clinical manifestation of chronic retention — the bladder is so full it "overflows." The patient may report constant dribbling or bed-wetting. This is different from urge incontinence (OAB) or stress incontinence (pelvic floor weakness).
10. Exam Intelligence
| Trap | Correct Understanding |
|---|---|
| "LUTS = BPH" | LUTS is non-specific. Can be caused by OAB, UTI, bladder cancer, neuropathy. LUTS ≠ BPH |
| "Large prostate = BOO" | Prostate size poorly correlates with BOO severity. Small prostates can cause significant obstruction |
| "Low Qmax = BOO" | Uroflowmetry cannot distinguish BOO from detrusor underactivity. Need pressure-flow study |
| "Never check PSA after AROU" | AUR/UTI can confound PSA. Defer or repeat after resolution under standardised conditions; do not abandon indicated cancer assessment |
| "BOO = clinical diagnosis" | BOO is a URODYNAMIC diagnosis (high Pdet + low Qmax) |
| "BPH predisposes to CA prostate" | No — BPH is transitional zone, CA prostate is peripheral zone |
| "Painless retention = acute" | Painless retention is usually CHRONIC |
| Overflow incontinence confused with urge incontinence | Overflow = chronic retention + dribbling; Urge = detrusor overactivity + sudden urge |
- α1-blocker vs 5-ARI: α1-blockers work within days (quick relief); 5-ARI takes 6-12 months (for large prostates)
- Uroflowmetry vs Pressure-flow study: Uroflowmetry = screening (Qmax only); Pressure-flow = diagnostic (Qmax + Pdet)
- IPSS vs urodynamics: IPSS = symptom severity tool; Urodynamics = objective diagnosis of BOO
- Urethral cath vs SPC: uncomplicated AUR usually starts with urethral drainage. Suspected urethral trauma requires RUG/cystoscopic assessment and expert diversion, not repeated blind attempts; percutaneous SPC requires a safely localised/distended bladder and trained placement
High Yield Summary
-
Normal micturition
- requires coordinated switching between storage (sympathetic ON, parasympathetic OFF, somatic ON) and voiding (parasympathetic ON, sympathetic OFF, somatic OFF), orchestrated by the PMC with cortical permission.
-
AROU
- = sudden, painful inability to void; most common in elderly men due to BPH. CROU = gradual, painless; often neuropathic.
-
Key receptors
- β3 (detrusor relaxation), α1 (bladder neck contraction), M3 (detrusor contraction), nicotinic (external sphincter contraction).
-
BOO is a urodynamic diagnosis
- low flow + high detrusor pressure. Uroflowmetry alone is insufficient.
-
BPH obstruction
- has static (anatomical — 5-ARI) and dynamic (smooth muscle — α-blocker) components.
-
Precipitating factors for AROU
- constipation, UTI, anaesthesia, immobility, drugs (anticholinergics, sympathomimetics), peri-anal conditions, alcohol.
-
Red flags in AROU
- lower limb weakness + faecal incontinence → spinal cord compression; bone pain + constitutional symptoms → metastatic CA prostate.
-
Management
- Immediate, free urethral drainage when safe → stop force if passage is difficult → expert/cystoscopic catheter or image-guided SPC; monitor high-volume/chronic retention and give an α blocker before planned TWOC when BPH is likely.
-
SPC contraindications
- non-distended bladder, uncorrected coagulopathy, suspected urothelial cancer.
-
Overflow incontinence
- = chronic retention + continuous dribbling — differentiate from urge incontinence (OAB) and stress incontinence (pelvic floor weakness).
Active Recall - Lecture Notes
[1] Lecture slides: GC 180. Benign prostatic hyperplasia, bladder outlet obstruction and urinary retention.pdf [2] Senior notes: Ryan Ho Urogenital.pdf (Section 8.3) [3] Senior notes: Maksim Surgery Notes.pdf (Section 2.4 LUTS & BPH); MBBS Final MB (Surgery) (Felix PY Lai).pdf (BPH chapter) [4] Lecture slides: GC 209. Urinary incontinence and overactive bladder.pdf (p30 - overflow incontinence)
Current guidance and primary evidence used for safety updates: EAU 2026 male LUTS — diagnostic evaluation; EAU male LUTS — disease management; EAU 2026 urological trauma; EAU prostate cancer — diagnostic evaluation; NICE CG97 — male LUTS; NICE NG113 — catheter-associated UTI; Boettcher et al. randomised decompression trial; AUA BPH guideline, 2023 amendment.
GC179 Anal Pain Perianal Lesions And Sepsis
Anal pain with perianal lesions and sepsis encompasses conditions such as perianal abscesses, fistulae, fissures, and thrombosed hemorrhoids that may present with localized pain, swelling, and potential systemic infection if inadequately treated.
GC181 Breast Mass Breast Cancer; Benign Breast Diseases; Mammography; Breast Cancer Screening
A breast mass is a localized swelling in the breast that may represent benign conditions such as fibroadenoma, fibrocystic changes, or cysts, or malignant disease such as breast carcinoma, evaluated through clinical examination, mammography, and tissue sampling as part of a triple assessment approach.